ERROR 1
ERROR 1
ERROR 2
ERROR 2
ERROR 2
ERROR 2
ERROR 2
Password and Confirm password must match.
If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)
ERROR 2
ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.
Mitsubishi Chemical has confirmed that its Mitsubishi Pharma subsidiary is holding merger talks with Tanabe Seiyaku Co., the result of which would be Japan's 6th largest drug company.
The firms have not come to any agreement, Mitsubishi Chemical says. But Nihon Keizai Shimbun, Japan's largest business newspaper, reports that the companies have already agreed to a framework under which Tanabe would take over Mitsubishi Pharma. In turn, Mitsubishi Chemical would acquire more than 50% of the merged entity, the report says.
There has not been a big drug merger in Japan since early in 2005 when Sankyo and Daiichi Pharmaceuticals decided to combine their operations. Mitsubishi Pharma and Tanabe both have strengths in drugs for circulatory diseases but have not launched major new products in recent years, the newspaper reported.
Meanwhile, Mitsubishi Chemical says its chief technology officer, Yoshimitsu Kobayashi, will become president and CEO on April 1. The current president and CEO, Ryuichi Tomizawa, will become chairman, a position that has been vacant since 2004 when the previous chairman, Kanji Shono, stepped down.
Join the conversation
Contact the reporter
Submit a Letter to the Editor for publication
Engage with us on Twitter